An International Publications House

Albert Science International Organization

Connecting People With Pioneering Thought

Albert Science International Organization (ASIO) is international , peer-reviewed , open access , cum print version & online journals.
Articles
Current
Archive
Special
Editorial Board
Paper In Publication Desk
Author Instruction
Author Desk
Call for Paper
Upcoming Journals and Books
Indexing of ASIO Journals
Author Instructions for Manuscript
Model Manuscript
Covering Letter
Publication Charges
Our Journals
ASIO Journal of Engineering & Technological Perspective Research (ASIO-JETPR) [ISSN: 2455-3794]
ASIO Journal of Medical & Health Sciences Research (ASIO-JMHSR)
ASIO Journal of Nursing & Physiotherapeutic Research (ASIO-JNPR)
ASIO Journal of Pharmaceutical & Herbal Medicines Research (ASIO-JPHMR) [ISSN: 2455-281X]
ASIO Journal of Microbiology, Food Science & Biotechnological Innovations (ASIO-JMFSBI) [ISSN: 2455-3751]
ASIO Journal of Chemistry, Physics, Mathematics & Applied Sciences (ASIO-JCPMAS) [ISSN: 2455-7064 ]
ASIO Journal of Humanities, Management & Social Sciences Invention (ASIO-JHMSSI) [ISSN: 2455-2224]
ASIO Journal of Analytical Chemistry (ASIO-JAC) [ISSN: 2455-7072]
ASIO Journal of Drug Delivery (ASIO-JDD) [ISSN: 2455-2828]
ASIO Journal of Experimental Pharmacology & Clinical Research (ASIO-JEPCR) [ISSN: 2455-7080]
ASIO Publication of Thesis & Dissertation (ASIO-PTD)
Health & Medicine Blog (ASIO)
JOURNALS || ASIO Journal of Drug Delivery (ASIO-JDD) [ISSN: 2455-2828]
A REVIEW ON FORMULATION AND DEVELOPMENT OF ANTIFUNGAL NAIL LACQUER

Author Names : Rohit Yadav
Page No. : 21-28
Read Hit : 791
Pdf Downloads Hit : 3  Volume 6 Issue 1
Article Overview

ARTICLE DESCRIPTION: 

Rohit Yadav, Ashish Srivastava, Pranveer Singh, A review on formulation and development of antifungal nail lacquer, ASIO Journal of Drug Delivery, 2022, 6(1): 21-28.

ARTICLE TYPE: REVIEW

DOI Link:: http://doi-ds.org/doilink/10.2016-21915953/ ; DOI Link :: https://doi-ds.org/doilink/10.2022-21959841/ASIO-JDD/10.2016-21915953/2022/V6/I1/923

ABSTRACT

Onychomycosis is the condition that affects the nail bed the most frequently. There is a possibility that dermatophytes, yeasts, or moulds that aren't dermatophytes caused it. Oral communication has traditionally played an Antifungal treatment have been used to try to treat the fungus, even though these treatments can make the fungus worse. It can be accompanied by adverse effects as well as interactions with other medications. Topical treatments we offer an alternative mode of administration in order to avoid the systemic effects of oral administration. The focus of recent research has been on the development of topical drugs and development in conjunction with one another, physical and laser treatments are being utilised. Topical agents, which might make it easier for the medication to penetrate the dense nail plate. In the following analysis, detailed below are procedures from each of the following categories: both unconventional and innovative. To determine the efficacy of, furtherstudies over longer time periods are required. Patients comply with various treatments, but they are more likely to recover when they comply with Follow all of the recommended preventative measures to keep the disease from returning Protein is the primary component of fingernails and toenails, both of which are essentially modified forms of hair. The nail is made up of various components, such as the nail matrix and the nail. Under the nail, the nail root is the part that is growing. The skin is located directly beneath the nail's proximal end. Eponychium or the stratum corneum is the structure of skin that is located at the proximal end of the body. Pertaining to both the skin and the paronychium, which would be the fold of the skin that is located on the edge of the nail The term for hyponychium is the junctures between the layers of skin that make up the right hand or toe, as well as the tip of the trailing edge of the nail. The nail plate, which is the tough where as the portion that can be seen through, is made of keratin.in addition to the connective tissue that is adhered to the nail bed.is the base of the nail. The lunula, which has the shape of a crescent, region of the toenail that is white in colour.
KEYWORDS: Onychomycosis, tinea pedis, dermatophyte, toenail, antifungal,Nail lacquer.

Reference
1. Vlahovic TC. Onychomycosis: evaluation, treatment options, managing recurrence, and patient outcomes. Clinics in podiatric medicine and surgery. 2016 Jul 1;33(3):305-18.
2. Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. Journal of the American Academy of Dermatology. 2019 Apr 1;80(4):853-67.
3. Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clinics in dermatology. 2010 Mar 1;28(2):151-9.
4. Thomas J, Peterson GM, Christenson JK, Kosari S, Baby KE. Antifungal drug use for onychomycosis. American Journal of Therapeutics. 2019 May 1; 26(3):388-96.
5. Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clinics in dermatology. 2010 Mar 1; 28(2):151-9.
6. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. Journal of the American Academy of Dermatology. 2000 Oct 1;43(4):641-8.
7. Lipner SR, Scher RK. Onychomycosis: Clinical overview and diagnosis. Journal of the American Academy of Dermatology. 2019 Apr 1;80(4):835-51.
8. Goldstein AO, Bhatia N. Onychomycosis: Epidemiology, clinical features, and diagnosis. In: Post TW, ed. Up To Date. Waltham, MA. (Accessed on June 30, 2019).
9. Grover C, Khurana A. Onychomycosis: Newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereol Leprol 2012; 78(3): 263-70.
10. Gupta AK, Foley KA. Evidence for biofilms in onychomycosis. G Ital Dermatol Venereol 2019; 154(1): 50-5.
11. Drago L, Micali G, Papini M, Piraccini BM, Veraldi S. Management of mycoses in daily practice. G Ital Dermatol Venereol. 2017 Dec;152(6):642-650. 
12. Maddy AJ, Tosti A. Hair and nail diseases in the mature patient. Clin Dermatol. 2018 Mar - Apr;36(2):159-166. 
13. Arsenijevi? VA, Denning DW. Estimated Burden of Serious Fungal Diseases in Serbia. J Fungi (Basel). 2018 Jun 25;4(3).
14. Lipner SR, Scher RK. Onychomycosis: Clinical overview and diagnosis. J Am Acad Dermatol. 2019 Apr;80(4):835-851. 
15. Evans EGV. The rationale for combination therapy. Br J Dermatol 2001;145(suppl 60):9–13. 4 
16. Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol 1999;12(suppl 1):S6–S9.
17. Del Palacio A, Cuetara MS, Garau M, et al. Onychomycosis: a prospective survey of prevalence and etiology in Madrid. Int J Dermatol 2006;45:874–876.
18. Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 2004;47:131–135.
19. Trepanier EF, Amsden GW. Current issues in onychomycosis.Ann Pharmacother 1998;32:204–214.
20. Barisic-Drusko V, Rucevic I, Biljan D, et al. Epidemiology of dermatomycosis in Eastern Croatia – today and yesterday. Coll Antropol 2003; 27(suppl 1):11–17.
21. Pichardo-Geisinger R., Mora D.C., Newman J.C., Arcury T.A., Feldman S.R., Quandt S.A. Comorbidity of tinea pedis and onychomycosis and evaluation of risk factors in Latino immigrant poultry processing and other manual laborers. South. Med. J. 2014;107:374–349. doi: 10.14423/01.SMJ.0000450705.67259.
22. Finch J., Arenas R., Baran R. Fungal melanonychia. J. Am. Acad. Dermatol. 2012; 66:830–841. doi: 10.1016/j.jaad.2010.11.018
23. Piraccini B.M., Tosti A. White superficial onychomycosis: Epidemiological, clinical, and pathological study of 79 patients. Arch. Dermatol. 2004; 140:696–701. doi: 10.1001/archderm.140.6.696. 
24. Piraccini B.M., Lorenzi S., Tosti A. ‘Deep’ white superficial onychomycosis due to molds. J. Eur. Acad. Dermatol. Venereol. 2002; 16:532–533. doi: 10.1046/j.1468-3083.2002.00559_1.x. 
25. Tosti A., Baran R., Piraccini B.M., Fanti P.A. “Endonyx” onychomycosis: A new modality of nail invasion by dermatophytes. Acta Derm. Venereol. 1999; 79:52–53. doi: 10.1080/000155599750011714. 
26. Clinical Knowledge Summaries. Fungal and candidal nail infections. Available from http://cks.library.nhs.uk/impetigo (Accessed January 2009).
27. How should fungal nail be treated? Drug Ther Bull 2008; 46(1): 3-8.
28. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003; 148: 402-10.
29. Elewski B E, Rinaldi M G, Weitzman I. Diagnosis and treatment of onychomycosis. a clinician’s handbook. Califon, N.J: Gardiner-Caldwell SynerMed; 1995.
30. Cohen J L, Scher R K, Pappert A S. The nail and fungus infections. In: Elewski B, editor. Cutaneous fungal infections. New York, N.Y: Igaku-Shoin Inc.; 1992. pp. 106–122.
31. Waikato Hospital. Available from http://www.waikatodhb.govt.nz/ laboratory/tests/microbiology_tests/mycology_skin_scrapings.htm
32. Olde Hartman TC, van Rijswijk E. Fungal nail infection. BMJ 2008; 337:295.
33. Waikato Hospital. Available from http://www.waikatodhb.govt.nz/ laboratory/tests/microbiology_tests/mycology_skin_scrapings.htm
34. Lewsli B. Onychomycosis: Pathogenesis, Diagnosis, and Management. Clin Microbiol Rev. 1998; 11(3):415–429.
35. Zalacain A, Obrador C, Martinez JP et al. Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain. Med Mycol J. 2010;49(5):495–499.
36. Ghannoum M, Isham N. Fungal nail infections (onychomycosis): a never-ending story?. PLoS Pathog. 2014;10(6):e1004105.
37. Shemer A, Sakka N, Baran R et al. Clinical comparison and complete cure rates of terbinafine efficacy in affected onychomycotic toenails. J Eur Acad Dermatol Venereol. 2015;29(3):521–526
38. Queller JN, Bhatia N. The dermatologist’s approach to onychomycosis. J Fungi. 2015; 1(2):173–184. 
39. Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014;7(7):10–18.
40. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000; 43(4 Suppl):57–69. 
41. Hafeez F, Hui X, Selner M et al. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers. Drug Dev Ind Pharm. 2013; 40(6):838–844. 
42. Tachibana H, Kumagai N, Tatsumi Y. Fungicidal activity in the presence of keratin as an important factor contributing to in vivo efficacy: a comparison of efinaconazole, tavaborole, and ciclopirox. J Fungi (Basel). 2017;3(4):pii: E58.
43. Baran JR, Hay R. Partial surgical avulsion of the nail in onychomycosis. Clin Exp Dermatol 1985; 10:413-8.
44. Rollman O, Johansson S. Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. Acta Derm Venereol (Stockh) 1987;67:506-10.